Lead-212
- Generic Name
- Lead-212
Targeted Alpha Therapy Shows Promise in Expanding Cancer Treatment Landscape
• Targeted alpha therapy (TAT) is emerging as a promising cancer treatment, delivering localized radiation to tumor cells while minimizing harm to healthy tissues.
• The FDA approval of Xofigo in 2013 for advanced prostate cancer marked a pivotal moment, spurring research into TAT for various solid tumors and hematological malignancies.
• Clinical trials are evaluating TAT candidates like RayzeBio's RYZ101 for neuroendocrine tumors and Actinium Pharmaceuticals’ Actimab-A for leukemia, showing potential in addressing unmet medical needs.
• TAT's precision and efficacy are attracting significant investments and regulatory support, positioning it as an integral component of precision medicine in oncology and beyond.
Sanofi, RadioMedix, and Orano Med Partner to Develop Radioligand Therapy for Rare Cancers
• Sanofi, RadioMedix, and Orano Med have entered an exclusive licensing agreement to develop AlphaMedix for rare cancers, focusing on neuroendocrine tumors (NETs).
• AlphaMedix, a targeted alpha therapy, has received FDA Breakthrough Therapy Designation for gastroenteropancreatic NETs in patients treatment-naive to peptide-receptor radionuclide therapy.
• Clinical studies have shown AlphaMedix to be well-tolerated, providing substantial tumor reduction with a 62.5% durable response rate, supporting potential regulatory filing.
• Sanofi will lead global commercialization, Orano Med will handle manufacturing, and RadioMedix and Orano Med will receive up to €320 million plus tiered royalties.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath